Fulgent Genetics Inc (7F0.MU)
| Previous Close | 20.60 |
| Open | 20.40 |
| Bid | 20.20 x N/A |
| Ask | 20.60 x N/A |
| Day's Range | 20.40 - 20.40 |
| 52 Week Range | 18.90 - 37.50 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | Aug 02, 2024 - Aug 06, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Business WireMoffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
TAMPA, Fla. & LOS ANGELES, May 14, 2024--Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. (NASDAQ: FLGT) and a leading nanobiotechnology company specializing in innovative cancer therapeutics, announced today a strategic partnership aimed at advancing cancer treatment through clinical development and pre-clinical co-development initiatives. This collaboration combines Moffitt’s cutting-edge clinical capabilit
Simply Wall St.Fulgent Genetics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Fulgent Genetics ( NASDAQ:FLGT ) First Quarter 2024 Results Key Financial Results Revenue: US$64.5m (down 2.5% from 1Q...
Insider MonkeyFulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2024 Earnings Call Transcript
Fulgent Genetics, Inc. (NASDAQ:FLGT) Q1 2024 Earnings Call Transcript May 3, 2024 Fulgent Genetics, Inc. beats earnings expectations. Reported EPS is $-0.01, expectations were $-0.33. Fulgent Genetics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Greetings, and welcome to […]
